Realizing that in-person meetings are back to the stage, Creative Biolabs, a specialized CRO, enthusiastically getting involved, has announced its participation in international networking events, taking along its mRNA solutions with new features.
New York, USA – April 25, 2022 – mRNA has gained booming attention since the successful approval of several COVID-19 mRNA vaccines as powerful prevention approaches against SARS-CoV-2 infection. Though the fast approval of those COVID-19 vaccines may leave an impression that the mRNA technology is young, it can be traced back as far as 1978, yet its full potential was only excavated not long ago. Creative Biolabs, having the insight that mRNA can shine at some point, started exploring the field of mRNA technology almost a decade ago, and is now fully capable to provide technical solutions such as mRNA modification.
“Projects from customers usually have divers research targets,” said a scientist, “and that’s the reason why we set all our solutions as customized.”
Creative Biolabs has diverse capabilities covering the core techniques involved in mRNA studies, such as synthesis, modification, delivery strategies, and therapeutics development of mRNA.
One of the “star” services can be mRNA synthesis, which is handled by specialists using chemical approaches or in vitro transcription methods. The underlying reason for which method is chosen lies in the length of the product desired. To be specific, when small fragments are the target, chemical synthesis is recommended, which is more cost-effective and efficient for producing gram scale quantity of mRNA. On the other hand, it is much more feasible to use IVT synthesis of mRNA fragments that are much longer.
As the inherent nature of in vitro synthetic mRNA lies in its instability as well as immunogenicity, Creative Biolabs take the modification of mRNA as core as well.
“Modifying mRNA is our signature dish,” noted the scientist. “By incorporating modified nucleotides at the 3′ end or doing an mRNA capping at the 5′ end, we can minimize the risks of mutagen and carcinogen effects of the desired mRNA.”
Substances involved in nucleotide modification are Pseudouridine, 2-Thiouridine, 5-Methylcytidine, and N6-Methyladenosine, and methodologies involved in mRNA 5′ capping can be ARCAs cap, fluorescent cap, etc.
“We have an all-around solution regarding mRNA technology, which is extending to other areas,” added the scientist, “and we’d like to showcase our capabilities in the coming meetings.”
Learn more about Creative Biolabs at https://mrna.creative-biolabs.com.
Creative Biolabs is a CRO with a history of more than 10 years. In 2022, a group of doctoral-level scientists will exhibit at international conferences to show Creative Biolabs’ strength in immunology areas.